Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis.

Ying ChenZhe ChenJunjie CaoLi LinJipeng Li

Published in: Hematology (Amsterdam, Netherlands) (2024)

The degree of immunoparesis during treatment is a follow-up indicator for survival in nontransplant myeloma patients, and severe and continuous immunoparesis in nontransplant myeloma patients might be a sign of poor prognosis.

Keyphrases

poor prognosis
newly diagnosed
end stage renal disease
long non coding rna
multiple myeloma
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
early onset
bone marrow
cell therapy
drug induced